Evaluating the effectiveness of sacituzumab govitecan in specific breast cancer patients

SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW/ULTRA LOW MetaStatic Breast Cancer

This study is testing if a drug called sacituzumab govitecan can help people with advanced hormone receptor-positive breast cancer who have already been treated with another medication.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Baptist Health South Florida (Academic / other)
• Drugs / interventions: chemotherapy, Immunotherapy, Radiation, sacituzumab, trastuzumab
• Locations: 3 sites (Los Angeles, California and 2 other locations)
• Trial ID: NCT06263543 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to assess the effectiveness of sacituzumab govitecan (SG) in patients with metastatic hormone receptor-positive (HR+)/HER2-low breast cancer who have previously been treated with trastuzumab deruxtecan (T-DXd). The study will involve patients who have advanced and unresectable breast cancer, and it will determine if SG remains effective at its approved dose and schedule in this specific patient population. Participants must meet specific eligibility criteria, including age and cancer characteristics, and will be monitored throughout the study for treatment response.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed metastatic HR+/HER2-low breast cancer who have previously received T-DXd.

Not a fit: Patients with HER2-positive breast cancer or those who have not received prior treatment with T-DXd may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide an effective treatment option for patients with advanced breast cancer who have limited alternatives.

How similar studies have performed: Other studies have shown promise in using antibody drug conjugates for breast cancer treatment, but this specific approach is novel.

Eligibility criteria

Inclusion Criteria:

* Provision of signed and dated informed consent form.
* Stated willingness to comply with all study procedures and availability for the duration of the study.
* Individuals ≥ 18 years of age.
* 4\. Histologically confirmed metastatic or advanced and unresectable breast cancer that is HER2 LOW/ULTRA LOW by local testing on either the primary or any metastatic site. HER2 LOW is defined as: (IHC 2+/ISH- or IHC 1+ (ISH- or untested)) and HER2 ULTRA LOW is defined as: IHC0+ (faint membrane staining up to 10%)
* Histologically confirmed metastatic or advanced and unresectable breast cancer that is hormone receptor positive (estrogen receptor and/or progesterone receptor positive) defined as \>1% on any metastatic site or the primary tumor.
* Endocrine-refractory (as per investigator judgement) and may have received any number of prior endocrine therapies (alone or in combination with cyclin-dependent kinase (CDK)4/6 inhibitor, everolimus, alpelisib, acapivasertib or inavolisib).
* Received a CDK4/6 inhibitor either alone or in combination with endocrine therapy (in the adjuvant or metastatic setting) with any duration of therapy permitted.
* Received at least 1 but no more than 4 prior systemic chemotherapy regimens in the metastatic setting. Prior ADCs count as a line of systemic chemotherapy. Prior PARP inhibitor use counts as a line of systemic therapy.
* Prior treatment with T-DXd (discontinued for progression and/or intolerance), which does not have to be the treatment immediately prior to enrollment on trial.
* Documented clinical and/or radiographic disease progression after most recent therapy, unless immediate prior therapy was T-DXd which was discontinued for toxicity.
* Measurable disease, as per RECIST V1.1 - a. If a patient has bone-only disease, they are eligible as long as there is a lytic lesion that is considered measurable. Blastic-only bone lesions are not allowed.
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.
* Adequate organ and bone marrow function within 28 days before enrollment. For all parameters listed below, the most recent results available must be used:

  1. Hemoglobin ≥ 9 g/dL. Note: Red blood cell transfusion is not allowed within 1 week prior to screening assessment.
  2. Absolute neutrophil count (ANC) ≥ 1500/mm\^3. Note: Granulocyte-colony stimulating factor (G-CSF) administration is not allowed within 1 week prior to screening assessment.
  3. Platelet count ≥ 100,000/mm\^3. Note: Platelet transfusion is not allowed within 1 week prior to registration.
  4. Total bilirubin (TBL) ≤ 1.5 × upper limit of normal (ULN) if no liver metastases or \< 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastasis at baseline.
  5. Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 3 ×ULN or \< 5 × ULN in patients with liver metastasis.
  6. Serum albumin ≥ 2.5 g/dL.
  7. Creatinine clearance (CrCl) ≥ 30 mL/min (calculated using the Cockcroft and Gault equation). Cockcroft-Gault equation: CrCl (mL/min) = \[140 - age (years)\] × weight (kg) 72 × serum creatinine (mg/dL) {× 0.85 for females}
  8. International normalized ratio (INR) or prothrombin time (PT) and either partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.
* Adequate treatment washout period before randomization, defined as:

  1. Major surgery: ≥ 3 weeks
  2. Radiation therapy including palliative and/or stereotactic radiation therapy ≥ 2 weeks
  3. Hormonal therapy: ≥ 2 weeks
  4. Targeted therapy (CDK4/6i, PARP inhibitor, AKTinhibitor, mTOR inhibitor, PIK3CA inhibitor): ≥ 2 weeks
  5. Immunotherapy (non-antibody-based therapy): ≥ 2 weeks
  6. T-DXd: ≥ 3 weeks
* Evidence of post-menopausal status or for individuals of childbearing potential must have a negative serum beta-human chorionic gonadotropin (ß-hCG) at screening or baseline. Individuals of childbearing potential are defined as those who are not surgically sterile (i.e., underwent bilateral tubal occlusion, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.
* Individuals of childbearing potential who are sexually active with a non-sterilized male partner must agree to use at least one highly effective method of contraception from the time of registration through final study treatment. Not all methods of contraception are highly effective.
* Non-sterilized male patients who are sexually active with a partner of childbearing potential must agree to use a condom with spermicide from registration and throughout duration of the study treatment.

The following are acceptable measures to prevent pregnancy:

* Abstinence (not having sexual relations with a person who can get you pregnant)
* Non-hormonal Intrauterine Device (IUD)
* Vasectomy
* Sterilization
* Bilateral tubal occlusion

Exclusion Criteria:

* Locally advanced MBC (stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment.
* Patients with brain metastases (BM) except for asymptomatic treated BM not requiring ongoing corticosteroid treatment with stable lesions on baseline/screening brain MRI. Patients who require treatment of brain metastases are eligible after 14 days post receipt of surgery or radiation, if felt to be clinically stable and not requiring ongoing corticosteroid treatment.
* Active serious infection requiring ongoing antibiotics.
* History of an anaphylactic reaction to irinotecan.
* Pregnant or breastfeeding.
* Ongoing treatment with another investigational drug or other interventional trial.
* Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
* Any other condition that may put a participant at higher risk, at the discretion of the investigator.

Where this trial is running

Los Angeles, California and 2 other locations

• UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (Not_yet_recruiting)
• Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida, United States (Recruiting)
• Winship Cancer Institute at Emory University — Atlanta, Georgia, United States (Recruiting)

Study contacts

• Principal investigator: Reshma L Mahtani, D.O. — Miami Cancer Institute at Baptist Health, Inc.
• Study coordinator: Reshma L Mahtani, D.O.

Conditions Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Hormone-receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Low Breast Cancer